corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library item: 12304

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

 

Publication type: news

New Approaches to Drug Development Will Drive Drug Company Success, According to Tufts Center for the Study of Drug Development
PharmaLive 2008 Jan 3
http://pharmalive.com/news/index.cfm?articleID=503418&categoryid=9&newsletter=1#


Full text:

Drug companies, under significant pressure to develop new prescription medicines faster and at lower cost, are more likely to succeed if they change the way they conduct R&D and manage projects, manufacturing, and marketing, according to the Tufts Center for the Study of Drug Development.

“The most successful developers in the near- and medium-term will be those that evolve their management and information systems to improve access to new development platforms and tools,” said Tufts CSDD Director Kenneth I Kaitin, who made his comments with the release today of the Tufts Center’s Outlook 2008 report on near-term pharmaceutical and biopharmaceutical trends.

“In the longer term, the successful companies will be those that radically overhaul their approach to business — from R&D to project management, manufacturing, and marketing,” he noted.

Kaitin acknowledged that the changes he advocates pose a high hurdle for drug developers, adding, “The pharmaceutical industry essentially has not changed its R&D paradigm in more than four decades, while nearly every other global industry has undergone major change within the last decade. The drug industry has little choice than to change the way it does business.”

Among the near-term trends cited in the Tufts CSDD’s Outlook 2008 report include the following:

  • Companies will continue to increase their investments in the development of personalized drugs and biologics, leading to an increased focus on diagnostic companies as potential partners and take-over targets. * The U.S. Food and Drug Administration (FDA) will be challenged to implement the FDA Amendments Act of 2007 in the wake of large staff turnovers, a new administration, as well as a vigilant and concerned public and Congress. * Drug sponsors will focus more attention on simplifying and streamlining study protocols to reduce study conduct delays and improve investigative site adherence and performance. * Interest in commercial cancer vaccine development will wane in the short term as more targeted cancer therapeutics, such as protein kinase inhibitors and monoclonal antibodies, reach the market. * U.S. policy makers will increasingly look to postmarketing studies that assess comparative clinical- and cost-effectiveness to make decisions on prescribing guidelines and drug reimbursement. * The European Medicines Agency and FDA will continue efforts to harmonize regulatory approaches in areas of common interest, such as pandemic vaccines, medicines for children, rare diseases, and cancer.

About the Tufts Center for the Study of Drug Development

The Tufts Center for the Study of Drug Development (http://csdd.tufts.edu) at Tufts University provides strategic information to help drug developers, regulators, and policy makers improve the quality and efficiency of pharmaceutical development, review, and utilization. Tufts CSDD, based in Boston, conducts a wide range of in-depth analyses on pharmaceutical issues and hosts symposia, workshops, and public forums, and publishes the Tufts CSDD Impact Report, a bi-monthly newsletter providing analysis and insight into critical drug development issues.

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.

Email a Friend








Far too large a section of the treatment of disease is to-day controlled by the big manufacturing pharmacists, who have enslaved us in a plausible pseudo-science...
The blind faith which some men have in medicines illustrates too often the greatest of all human capacities - the capacity for self deception...
Some one will say, Is this all your science has to tell us? Is this the outcome of decades of good clinical work, of patient study of the disease, of anxious trial in such good faith of so many drugs? Give us back the childlike trust of the fathers in antimony and in the lancet rather than this cold nihilism. Not at all! Let us accept the truth, however unpleasant it may be, and with the death rate staring us in the face, let us not be deceived with vain fancies...
we need a stern, iconoclastic spirit which leads, not to nihilism, but to an active skepticism - not the passive skepticism, born of despair, but the active skepticism born of a knowledge that recognizes its limitations and knows full well that only in this attitude of mind can true progress be made.
- William Osler 1909